Correspondence 0001193125-24-130690 from Prelude Therapeutics Inc (PRLD) (CIK 0001678660) (PRLD)
Prelude Therapeutics Inc (PRLD) (CIK 0001678660)
Date: May 3, 2024 · CIK: 0001678660 · Accession: 0001193125-24-130690
AI Filing Summary & Sentiment
File numbers found in text: 333-277123
Letter
PRELUDE THERAPEUTICS INCORPORATED
175 Innovation Boulevard
Wilmington, Delaware 19805
May 3, 2024
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, DC 20549
Attention: Alan Campbell
Re: Prelude Therapeutics Incorporated (the “Registrant”), Registration Statement on Form S-3 (File No. 333-277123) filed February 16, 2024.
Ladies and Gentlemen:
Reference is made to our letter, filed with the Securities and Exchange Commission (the “Commission”) as correspondence via EDGAR on May 1, 2024 in which we requested the effective date of the above-captioned Registration Statement on Form S-3 be accelerated so that it would be declared effective at 4:30 PM, Eastern Time, on May 3, 2024, or as soon as thereafter practicable.
The purpose of this letter is to memorialize our conversations with the Commission in which we advised that we are not seeking effectiveness of the above-captioned Registration Statement on Form S-3 at the above requested time and that we intend to resubmit our request for acceleration of effectiveness at a later date.
We hereby formally withdraw our request for acceleration of the effective date at 4:30 PM, Eastern Time, on May 3, 2024.
[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]
Sincerely,
Prelude Therapeutics Incorporated
Show Raw Text
CORRESP 1 filename1.htm CORRESP PRELUDE THERAPEUTICS INCORPORATED 175 Innovation Boulevard Wilmington, Delaware 19805 May 3, 2024 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Attention: Alan Campbell Re: Prelude Therapeutics Incorporated (the “Registrant”), Registration Statement on Form S-3 (File No. 333-277123) filed February 16, 2024. Ladies and Gentlemen: Reference is made to our letter, filed with the Securities and Exchange Commission (the “Commission”) as correspondence via EDGAR on May 1, 2024 in which we requested the effective date of the above-captioned Registration Statement on Form S-3 be accelerated so that it would be declared effective at 4:30 PM, Eastern Time, on May 3, 2024, or as soon as thereafter practicable. The purpose of this letter is to memorialize our conversations with the Commission in which we advised that we are not seeking effectiveness of the above-captioned Registration Statement on Form S-3 at the above requested time and that we intend to resubmit our request for acceleration of effectiveness at a later date. We hereby formally withdraw our request for acceleration of the effective date at 4:30 PM, Eastern Time, on May 3, 2024. [REMAINDER OF PAGE INTENTIONALLY LEFT BLANK] Sincerely, Prelude Therapeutics Incorporated By: /s/ Bryant Lim Bryant Lim Chief Legal Officer, Corporate Secretary, and Interim Chief Financial Officer cc: Kris Vaddi, Chief Executive Officer Prelude Therapeutics Incorporated Robert Freedman, Esq. Julia Forbess, Esq. Fenwick & West LLP